Role of the association of high-risk HPV identified by real-time PCR in cervical preneoplastic lesions

Objective: To evaluate the effects of infection in multiple types of high-risk human papilloma virus (HPV) in cervical preneoplastic lesions in patients undergoing colposcopy following a diagnosis of atypical squamous cells of unknown significance (ASCUS) and low-grade squamous intraepithelial (LSIL) cytology. Materials and Methods: Between 2009 and 2010, 2,500 patients were recruited with a mean age of 35 +/- 5 years. Screening for cervical cancer was performed and in case of ASCUS and LSIL the patients underwent colposcopy. The tests for the detection and typing of viral DNA (HPV - DNA test) were performed on cervical swab with real-time PCR amplification. Results: The prevalence of infection was 70% (1579/2256) in the patients recruited. In relation to the degree of preneoplastic lesions some high-risk HPV viral genotypes were identified: HPV 16 (319/1466), HPV 18 (164/1466). HPV 45 (76/1466), HPV 31 (215/1466), HPV 52 (145/1466), HPV 58 (55/1466) HPV 56 (79/1466), HPV 51 (110/1466), HPV 6 (138/1466), HPV 11 (88/1466), HPV 42 (34/1466), HPV 53 (43/1466). In case of high-grade lesions of CIN (CIN2 and CIN3) a greater HPV co-infection was detected and in particular the association from 16 to 18 (70%), 16-33 (18%) and 16 to 52 (12%). Conclusions: Infection caused by the simultaneous presence of multiple HPV genotypes appears to be associated with a significantly increased risk of high-grade lesions of CIN or invasive cancer than the presence of single viral infections. The infection with multiple HPV types is a significant risk factor for high-grade lesions of CIN in women undergoing colposcopy for ASCUS cytology / LSIL. The use of real-time PCR has shown the ability not only to identify the different types of HPV, but also to monitor quantitatively the same over time, and during the study phase, to evaluate the sensitivity and specificity of the method in comparison with other techniques.

Squamous cell carcinoma; Endometrial carcinoma; Ichthyosis uteri

[1] Corneanu L.M., Sta˘nculescu D., Corneanu C., Rom J.: “HPV and cervical squamous intraepithelial lesions: clinico pathological study”. Morphol. Embryol., 2011, 52, 89.

[2] Chironna M., Neve A., Sallustio A., De Robertis A., Quarto M., Germinario C. et al.: “Frequency of human papillomavirus infection and genotype distribution among women with knowncytological diagnosis in a Southern Italian region. HPV Study Group”. J. Prev. Med. Hyg., 2010, 51, 139.

[3] Nasser H., Hayek S., Balasubramaniam M., Kuntzman T.J.: “Infectious organisms on papanicolaou smears should not influence the diagnosis of atypical squamous cells of undetermined significance”. Acta Cytol., 2011, 55, 251.

[4] López M.J., Ili G.C.G., Brebi M.P., García M.P., Capurro V.I., Guzmán G.P., Suárez P.E., Ojeda F.J.M., Roa S.J.C.: “Human papillomavirus genotyping of cervical uterine preneoplastic lesions in a high-risk area”. Rev. Med. Chil., 2010, 138, 1343.

[5] Bosch F.X., Burchell A.N., Schiffman M., Giuliano A.R., de Sanjose S., Bruni L. et al.: “Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia”. Vaccine, 2008, 26 (suppl. 10), K1.

[6] Trope A., Sjoborg K., Eskild A., Cuschieri K., Eriksen T., Thoresen S. et al.: “Performance of human papillomavirus (HPV) DNA and mRNA testing strategies in women with and without cervical neoplasia”. J. Clin. Microbiol., 2009, 47, 2458.

[7] Kuramoto H., Sugimoto N., Iida M.: “Screening for cancer of the cervix with simultaneous pap smear and colposcopy. The efficacy of pap smear and colposcopy”. Eur. J. Gynaecol. Oncol., 2011, 32, 73.

[8] Roberts C.C., Swoyer R., Bryan J.T., Taddeo F.J.: “Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection”. J. Clin. Microbiol., 2011, 49, 1899.

[9] Carcopino X., Bolger N., Henry M., Mancini J., Boubli L., Olive D. et al.: “Evaluation of type-specific HPV persistence and highrisk HPV viral load quantitation in HPV positive women under 30 with normal cervical cytology”. J. Med. Virol., 2011, 83, 637.

[10] Pierik A., Zwanenburg C., Moerland E., Broer D., Stapert H., van den Brule A.J.: “Rapid genotyping of human papillomavirus by post-PCR array-based hybridization techniques”. J. Clin. Microbiol., 2011, 49, 1395.

[11] Jaberipour M., Samsami A., Sahraiian F., Kazerooni T., Hashemi M., Ghaderi A., Habibagahi M.: “Elevation of HPV-18 and HPV-16 DNA in the plasma of patients with advanced cervical cancer”. Asian Pac. J. Cancer Prev., 2011, 12, 163.

[12] Stoler M.H., Wright T.C. Jr., Sharma A., Apple R., Gutekunst K., Wright T.L.: “High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study”. ATHENA (THE Need for Advanced HPV Diagnostics) HPV Study Group. Am. J. Clin. Pathol., 2011, 135, 468.

[13] Gudleviciene Z., Sepetiene A., Didziapetriene J., Valuckas K.P., Smailyte G., Drasutiene G., Nadisauskiene R.J.: “Prevalence of human papillomavirus types in cervical intraepithelial lesions”. Medicina (Kaunas), 2010.

[14] Calore E.E., Giaccio C.M., Nadal S.R.: “Prevalence of anal cytological abnormalities in women with positive cervical cytology”. Diagn. Cytopathol., 2011, 39, 323.

[15] Carter J.S., Sage Y.H., Vragovic O., Rosen L., Stier E.A.: “Effect of patient age on outcomes and compliance in women with minimally abnormal pap tests”. J. Reprod. Med., 2010, 55, 35.

[16] Muñoz N., Bosch F.X., Castellsagué X., Diaz M., de Sanjose S., Hammouda D. et al.: “Against which human papillomavirus types shall we vaccinate and screen?”. Int. J. Cancer, 2004, 111, 278.

[17] Um T.H., Lee E.H., Chi H.S., Kim J.W., Hong Y.J., Cha Y.J.: “Comparison of HPV genotyping assays and Hybrid Capture 2 for detection of high-risk HPV in cervical specimens”. Ann. Clin. Lab. Sci., 2011, 41, 48.

[18] Einstein M.H., Garcia F., Mitchell A.L., Day S.P.: “Age-stratified performance of the cervista(R) HPV 16/18 genotyping test in women with ASC-US cytology”. Cancer Epid. Biomark. Prev., 2011, 201, 1185.

[19] Chernesky M., Jang D., Portillo E., Smieja M., Chong S., Buracond S. et al.: “Comparative evaluation of AMPLICOR HPV PCR and linear array assays on surepathliquid-based Pap samples for the detection of high-risk HPV genotypes”. J. Clin. Virol., 2011, 50, 201.

[20] Cuschieri K.S., Cubie H.A., Whitley M.W., Seagar A.L., Arends M.J., Moore C. et al.: “Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population”. J. Clin. Pathol., 2004, 57, 68.

[21] Trottier H., Mahmud S., Costa M.C., Sobrinho J.P., Duarte-franco E., Rohan T.E. et al.: “Human papillomavirus infection with multiple types and risk of cervical neoplasia”. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 1274.

[22] Wheeler C.M., Hunt W.C., Schiffman M., Castle P.E.: “Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer”. J. Infect. Dis., 2006, 194, 1291.

[23] Koshiol J., Lindsay L., Pimenta J.M., Poole C., Jenkins D., Smith J.S.: “Persistent human papillomavirus infection and cervical neoplasia: a systematic review and metaanalysis”. Am. J. Epidemiol., 2008, 168, 138.

[24] Spinillo A., Dal Bello B., Gardella B., Roccio M., Dacco' M.D., Silini E.M.: “Multiple human papillomavirus infection and high grade cervical intraepithelial neoplasia among women with cytological diagnosis of atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions”. Gynecol. Oncol., 2009, 113, 115.